{"type":"trials","record":{"id":42123,"source_id":"clinicaltrials-gov","external_id":"NCT02684578","title":"Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD","brief_summary":"The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"University of California, San Francisco","enrollment":66,"countries":["United States"],"start_date":"2016-04-01","completion_date":"2022-10-01","last_update_date":"2023-06-09","source_url":"https://clinicaltrials.gov/study/NCT02684578","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"METforMIN","age_range":"55 Years","comparator":"Observe","organization":"University of California, San Francisco","interventions":["Metformin"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0 months, 18 months","Change in Best Corrected Visual Acuity (BCVA) — 0 months, 18 months","Change in Low-luminance Visual Acuity (LLVA) — 0 months, 18 months","Ocular Safety as Measured by the Presence of Novel Intraocular Inflammation Judged by the Investigator to be Due to the…","Systemic Safety as Measured by Presence of Side Effects Listed on Metformin Drug Label as \"Severe\" — 0 months, 6 months…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","source_has_results":true},"controlled_terms":["Age-Related Macular Degeneration","Macular Degeneration, Age-Related","Dry Macular Degeneration","Geographic Atrophy","Metformin"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02684578","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2016-04-01 to 2022-10-01","comparator":"Observe","confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.923Z","intervention":["Metformin"],"participants":66,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0 months, 18 months","Change in Best Corrected Visual Acuity (BCVA) — 0 months, 18 months","Change in Low-luminance Visual Acuity (LLVA) — 0 months, 18 months","Ocular Safety as Measured by the Presence of Novel Intraocular Inflammation Judged by the Investigator to be Due to the…","Systemic Safety as Measured by Presence of Side Effects Listed on Metformin Drug Label as \"Severe\" — 0 months, 6 months…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42123","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}